At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
06938 RIBOLIFE-B
Not Yet Opened 09-17 16:08:09
51.350
+0.050
+0.10%
High52.800
Low50.650
Vol269.40K
Open52.000
D1 Closing51.300
Amplitude4.19%
Mkt Cap8.73B
Tradable Cap8.73B
Total Shares170.00M
T/O13.90M
T/O Rate0.16%
Tradable Shares170.00M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Loading ...
Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.
RIBOLIFE-B Repurchases 181,600 H-Shares; Treasury Holding Rises to 0.57% of Issued Capital
Hong Kong Stock Market Movers | RIBOLIFE-B (06938) Surges Over 9% on Hang Seng Composite Index Inclusion, First-Half Revenue Expected to Rise Up to 3.2-Fold
Suzhou Ribo Life Science Co Ltd is a China-based company primarily engaged in the oligonucleotide research and development, with a focus on small interfering ribonucleic acid (siRNA) therapeutics. The Company is engaged in the oligonucleotide drug innovation focused on cardiovascular, metabolic, renal and liver diseases, as well as other therapeutic areas. The Company’s drug pipelines include RBD4059, RBD5044, RBD7022, RBD7007, RBD2080, RBD1119, RBD1016 and others. The Company mainly conducts its business in the domestic market.